Suppr超能文献

整合胆汁酸代谢组学与肠道微生物群以研究岩黄连总生物碱的抗肝纤维化作用。

Integration bile acid metabolomics and gut microbiome to study the anti-liver fibrosis effects of total alkaloids of Corydalis saxicola Bunting.

作者信息

Wang Qianyi, Zhang MeiLing, Meng Mingwei, Luo Zhuo, Pan Ziping, Deng Lijun, Qin Jinghua, Guo Bingjian, Zhu Dan, Zhang Yanmin, Guo Hongwei, Liang Yonghong, Su Zhiheng

机构信息

Department of Pharmacy, Guangxi Medical University Cancer Hospital, Nanning, 530021, China.

Pharmaceutical College, Guangxi Medical University, Nanning, 530021, China.

出版信息

Chin Med. 2025 Jul 4;20(1):106. doi: 10.1186/s13020-025-01158-2.

Abstract

BACKGROUND

Bile acids and gut microbiota participate in the pathogenesis of liver fibrosis (LF). The total alkaloids of Corydalis saxicola Bunting (TACS) is a traditional Chinese medicine extract that has been used to treat LF, but the underlying mechanisms are not clear. This study performed integrated metabolomics and gut microbiome analysis to study the anti-LF mechanism of TACS using a rat model.

METHODS

Ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to identify the chemical compounds in TACS. Biochemical and histopathological analysis were performed to determine the efficacy of TACS. Bile acid-targeted metabolomics was used to assess changes in the bile acid (BA) profiles in TACS-treated LF rats. 16S rRNA gene sequencing and metagenomics were used to assess changes in the gut microbiota of the TACS-treated LF rats. Antibiotic cocktail treatment and fecal microbiota transplantation (FMT) were used to determine the relationship between the gut microbiota and the anti-LF effects of TACS. Metagenomics was used to identify significantly enriched gut microbiota after TACS treatment and its correlation with the anti-LF effects was verified by in vivo experiments.

RESULTS

TACS treatment significantly reduced the levels of serum liver enzymes, fibrosis and pro-inflammatory cytokines in the liver. TACS significantly increased the levels of chenodeoxycholic acid (CDCA) and taurochenodeoxycholic acid (TCDCA) in the cecum and decreased the levels of cholic acid (CA) and deoxycholic acid (DCA) in the liver of the LF rats. TACS significantly increased the abundances of Lactobacillus and Akkermansia in the LF rats. Antibiotic cocktail treatment and FMT have shown that the effect of TACS cure liver fibrosis depends on the gut microbiota. The abundance of Lactobacillus reuteri was significantly increased by TACS. Administration of Lactobacillus reuteri via gavage ameliorated LF.

CONCLUSIONS

TACS exerted anti-LF effects in rats by modulating bile acid metabolism and gut microbiome.

摘要

背景

胆汁酸和肠道微生物群参与肝纤维化(LF)的发病机制。岩黄连总生物碱(TACS)是一种用于治疗LF的中药提取物,但其潜在机制尚不清楚。本研究采用大鼠模型,通过整合代谢组学和肠道微生物组分析来研究TACS的抗LF机制。

方法

采用超高效液相色谱四极杆飞行时间质谱(UPLC-Q-TOF/MS)鉴定TACS中的化学成分。进行生化和组织病理学分析以确定TACS的疗效。采用胆汁酸靶向代谢组学评估TACS治疗的LF大鼠胆汁酸(BA)谱的变化。采用16S rRNA基因测序和宏基因组学评估TACS治疗的LF大鼠肠道微生物群的变化。使用抗生素鸡尾酒治疗和粪便微生物群移植(FMT)来确定肠道微生物群与TACS抗LF作用之间的关系。采用宏基因组学鉴定TACS治疗后显著富集的肠道微生物群,并通过体内实验验证其与抗LF作用的相关性。

结果

TACS治疗显著降低了血清肝酶、肝脏纤维化和促炎细胞因子水平。TACS显著提高了盲肠中鹅去氧胆酸(CDCA)和牛磺鹅去氧胆酸(TCDCA)的水平,并降低了LF大鼠肝脏中胆酸(CA)和脱氧胆酸(DCA)的水平。TACS显著增加了LF大鼠中乳酸杆菌属和阿克曼氏菌属的丰度。抗生素鸡尾酒治疗和FMT表明,TACS治疗肝纤维化的效果取决于肠道微生物群。TACS显著增加了罗伊氏乳杆菌的丰度。通过灌胃给予罗伊氏乳杆菌可改善LF。

结论

TACS通过调节胆汁酸代谢和肠道微生物群对大鼠发挥抗LF作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/40e7/12226865/4aebd7048bd9/13020_2025_1158_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验